London,
United Kingdom, October 26, 2004
IMPAC Medical Systems,
(NASDAQ:IMPCE), a leading provider of information technology
solutions for oncology care, announced today that the London
Oncology Clinic LLP has selected IMPAC's specialised chemotherapy
electronic charting, practice manage-
ment, and statistical analysis solutions for its newly refurbished
clinic at 95 Harley Street. IMPAC's comprehensive oncology
information system is designed specifically to help chemotherapy
centres by providing process automation tools that improve process
efficiencies while reducing the risk of medical errors.
According to Dr Maurice Slevin, consultant oncologist and one of
the founding partners of the London Oncology Clinic, IMPAC was
selected because of their ability to understand the unique
requirements of delivering cancer care and translate those needs
into valuable software solutions. Dr Slevin stated, "The workflow
of the system complements the oncologist and nurse, and their
interaction with patients. All of the information currently stored
in paper charts will be converted into an electronic format to
enable immediate access by the entire staff, with appropriate
security levels, whenever and wherever needed. The breadth and
ease of access to this treatment information is unparalleled."
From initial diagnosis and staging through planning, treatment,
and subsequent follow up, the system will help staff accurately
record and efficiently process critical data throughout the
patient's complete cycle of care. "We are very pleased to partner
with a prestigious site such as the London Oncology Clinic," said
David Auerbach, president of IMPAC's International Operations.
"The integration of IMPAC's chemotherapy electronic charting
system will provide the London Oncology Clinic with leading-edge
tools to improve patient care by managing the entire spectrum of
critical patient data."
Irena Goldman, chief executive of the London Oncology Clinic
stated, "Our plans for future growth are well supported by IMPAC's
system with its built-in capability to accommodate both
chemotherapy and radiotherapy patient treatment planning, all
within a single application. A further critical factor in our
decision making was that IMPAC allows for full integration with
secure external data sources such as complex pathology testing,
and radiology. This will provide our consultants with a complete
and holistic view of their individual patients; a service central
to the
core values and motivation behind the inception of the London
Oncology Clinic."
IMPAC was founded in 1990 to develop an integrated clinical and
administrative management system tailored specifically for cancer
care and now has more than 2500 installations in 56 countries
worldwide - including over half of the top North American cancer
centres. IMPAC's chemotherapy electronic charting and order
management solution will be on display at the annual European
Society for Medical Oncology (ESMO) meeting in Vienna, Austria
from 30 October through 2 November 2004.
IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a leading provider of oncology IT
solutions that streamline both clinical and business operations to
help improve the process of delivering quality patient care. With
systems designed for anatomic pathology, medical oncology,
radiation oncology, imaging, clinical laboratory, and cancer
registry, IMPAC supports the entire team of healthcare
professionals who contribute to the care of the cancer patient.
Supporting more than 2500 installations worldwide, IMPAC provides
practical solutions that deliver better overall communication,
process efficiency and quality patient care. For more information
about IMPAC products and services, please call +1-650-623-8800 or
visit www.impac.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's review of its revenue recognition policies
and the estimated impact of the proposed financial restatement of
previously report results, possible delisting from The NASDAQ
Stock Market, business strategy, timing of, and plans for, the
introduction of new products and enhancements, future sales,
market growth and direction, competition, market share, revenue
growth, operating margins and profitability. All forward looking
statements included in this document are based upon information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward looking
statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, our inability to recognize revenue from
multiple element software contracts where certain elements have
been delivered, installed and accepted but other elements remain
undelivered, lost sales or lower sales prices due to competitive
pressures, the ability to integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, changes in Medicare reimbursement
policies, the integration and performance of acquired businesses,
and other factors and risks discussed in the 10 K/A and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
